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Abstract 
Human soluble galactose-binding lectin (galectin-1) has been expressed as an Escherichia coli fusion protein, following the 
amplification by polymerase chain reaction of cDNA prepared from a human osteosarcoma cell line. The fusion protein is a functional 
/3-galactoside-binding lectin, as is the recombinant galectin when purified from the cleaved fusion protein. The recombinant galectin has a 
biphasic effect on cell proliferation. Unlike the fusion protein, it functions as a human cell growth inhibitor, confirming earlier findings 
with natural human galectin-1, though it is less effective than the natural galectin. This reaction is not significantly inhibited by lactose, 
and is thus largely independent of the /3-galactoside-binding site. At lower concentrations, recombinant galectin-I is mitogenic, this 
activity being susceptible to inhibition by lactose, and thus attributable to the /3-galactoside-binding ability of the protein. Some tumour 
cells are susceptible to the growth-inhibitory effect, and the galectin-1 gene is expressed in both normal and tumour cells. 
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I. Introduction 
There is evidence for the existence of endogenous 
growth-related proteinases [1,2]. One such enzyme, the 
so-called growth-related proteinase (GRP), has been sub- 
jected to some functional characterisation. Antibodies to 
this enzyme inhibited the growth of many human cell 
types in culture, as did specific macromolecular p oteinase 
inhibitors [3-6]. Investigations into the effects of GRP 
inhibition on intracellular signalling pathways have re- 
cently been summarised, but no firm conclusions as to a 
site of action can yet be drawn [7]. Though there were 
early indications that thrombin might mimic the GRP [3], it 
now seems clear that the GRP does not interact with the 
thrombin receptor [7,8]. 
A report of a small, negative growth-regulatory protein 
produced by human fibroblasts howed that its effect could 
apparently be mimicked by an exogenous proteinase in- 
hibitor [9]. We considered it possible that the role of the 
proteinase inhibitor was to protect rather than to mimic the 
growth regulator. Another endogenous negative growth 
regulator, first identified in mouse fibroblasts [10], was 
extensively characterised and shown to be a /3- 
galactoside-binding protein (mGBP) [11]. The lability of 
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the mGBP suggested the possibility that it might be a 
substrate for a proteinase such as the mouse homologue of 
the GRP. Using human cells, we have obtained some 
circumstantial evidence to support this hypothesis. A /3- 
galactoside-binding protein was isolated from human fi- 
broblast conditioned medium by affinity chromatography. 
Yields of the protein were very low, but were increased in 
cultures treated with GRP inhibitors. The purified protein 
acted as a cellular growth inhibitor [12]. 
In order to extend this work, it was necessary to have 
access to a recombinant form of the GBP. The human 
homologue of mGBP has been cloned on several occa- 
sions, and we chose the human hepatoma cDNA sequence 
reported by Abbott and Feizi [13] as the starting point for 
the expression of recombinant hGBP. It should be noted 
that the animal /3-galactoside-binding soluble lectins, of 
which GBP is one, have had a diverse and confusing 
nomenclature. A recent, well-supported proposal suggests 
that these lectins be referred to as 'galectins' [14]. The 
GBP protein is designated 'galectin-l ' ,  and we shall use 
this name henceforth. 
Galectins, like other lectins, act as mitogens for a 
variety of cells, including spleen cells [15], lymphocytes 
[16] and vascular cells [17]. There is evidence in each case 
for inhibition of the mitogenic effect at supra-optimal 
galectin concentrations. It is possible that this inhibitory 
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phase may correspond to the specific growth-inhibitory 
activity more recently reported [11,12]. Further to this 
mitogenic activity, growth stimulation was also observed 
when bovine corneal endothelial cells were treated with 
human galectin [12]. Growth-stimulatory activity in a po- 
tentially therapeutic growth inhibitor is obviously worthy 
of investigation, irrespective of the intrinsic interest in a 
biphasic growth-modulatory protein acting on human cells. 
We describe the production, amplification and cloning 
of human galectin-I cDNA, its expression as a bacterial 
fusion protein, and the effect of the purified recombinant 
protein on the growth of human cells in culture. The 
production of a galectin-glutathione-S-transferase fusion 
protein was of particular value in this study, as it retained 
lectin function, but was not a growth inhibitor, whereas the 
separated recombinant galectin displayed both activities. 
2. Materials and methods 
2.1. Cell culture 
The MPS fibroblast cell strain is a normal human 
diploid fibroblast strain previously used by us in many 
experiments on growth-related proteolysis [5]. Tumour cell 
lines used included HELA and HEP 2 (human carcinomas), 
and U20S and MG 63 (human osteosarcomas), also 
previously used in such studies [6,18]. 
The conditions for maintenance and culture of cells 
have been previously described, as have assays for inhibi- 
tion of cell proliferation i  microwell culture plates, using 
an ELISA spectrophotometer to measure fixed and stained 
cells [19], and the assay of [3H]thymidine incorporation 
into DNA [20]. In cell proliferation assays, recombinant 
galectin-1, the GST-galectin fusion protein, or GST itself 
were added to normal culture media at known concentra- 
tions. In some experiments, lactose (100 mM) was also 
added; control experiments established that this did not 
affect cell viability or proliferation. Thymidine incorpora- 
tion was measured in confluent, quiescent well-plate cul- 
tures, to which proteins and lactose were added as appro- 
priate. Cell viability was tested by Trypan Blue exclusion 
in confluent fibroblast monolayer cultures, using a 0.04% 
dye solution in sodium phosphate-buffered isotonic saline 
(PBS). 
2.2. Cloning and expression of the galectin-1 gene 
Unless otherwise noted, DNA-modifying enzymes were 
purchased from Life Technologies and all other reagents 
were from Sigma. The plasmid expression vector pGEX 
4T-1 [21] and E. coli DH 5c~ cells were donated by Dr. 
David Christie. We used protocols described by Sambrook 
et al. [22] for techniques uch as DNA restriction and 
ligation, bacterial transformation, and agarose gel elec- 
trophoresis. 
Isolation of cytoplasmic RNA from mammalian cells 
was done initially using confluent cultures of human U2-OS 
osteosarcoma cells by a rapid method [23]. The extracted 
RNA was used as a template for a reverse transcription 
reaction performed using a RiboClone cDNA Synthesis 
System with AMV reverse transcriptase (Promega). The 
resulting cDNA was used as a template for PCR reactions 
with two pairs of convergent primers. To design these 
oligonucleotides, we referred to the sequence of the cDNA 
of human /3-galactoside-binding lectin from Hep G2 cells 
[16]. For initial experiments, the primers were 5'-CTGGA- 
GATCTTCATGGCTI'GTGGTCTG-3' and 5'-TGGCAGA- 
TCTCAGTCAAAGGCCACACA-3', and resulted in the 
production of a DNA fragment of approximately 450-bp in 
an agarose gel. The fragment was cloned into Bluescript, 
and sequenced by a modified Sanger technique using a 
373A Sequencer (ABI) in the Sequencing Unit of the 
School of Biological Sciences, confirming the reported 
sequence. With a view to bacterial expression of the 
galectin, new primers were designed, introducing a Barn HI 
site in the GBP3 primer and a Sal I site in the GBP4 
primer to permit cloning the amplified product into the 
pGEX vector. The GBP3 and GBP4 primers were, respec- 
tively, 5'-CGTGGATCCATGGCTTGTGGTCTGGTC-3' 
and 5'-ACGCGTCGACTCAGTCAAAGGCCACACA-3'. 
Conditions for PCR were 500 mM KC1, 1.5 mM MgC12, 
100 mM Tris-HC1, pH 8.8, 250 mM dNTPs (Pharmacia), 
20 pmol of each primer, 1.25 U Ampli Taq DNA poly- 
merase (Perkin Elmer) and 30 cycles of amplification 
(denaturing at 95°C for 1 rain, annealing at 55°C for 90 s 
and polymerizing at 72°C for 90 s). The amplified product 
was run on a 1.5% agarose horizontal gel in TAE buffer, 
cut out of the gel and purified using a Geneclean II kit 
(Bresatech). The product was restricted with Barn HI and 
Sal I restriction enzymes and ligated using T4 DNA ligase 
into the pGEX 4T-1 vector restricted with the same en- 
zymes, then transformed into competent E. coli DH 5a 
cells. 
Transformants were screened for the presence of the 
insert by growing l0 ml overnight cultures from several 
transformant colonies and using a Wizard miniprep DNA 
purification system (Promega) to isolate plasmid DNA 
which was later Barn HI/Sal I restricted and run on a 
1.5% agarose gel. The clones having the 450 bp insert 
were grown in 500 ml overnight cultures and the plasmid 
purified by equilibrium centrifugation i  CsCl-ethidium 
bromide gradients [22] and then sequenced, as previously 
described. 
2.3. Production of recombinant galectin-1 
One of the several transformants having the insert was 
then innoculated in 3 ml LB/ampicillin medium and 
grown at 37°C in a shaking incubator until the absorbance 
at 600 nm reached 0.8. At this stage the cultures were 
induced for 3 h with 1 mM IPTG and then microfuged for 
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10 min at 5000 rpm. The cell pellets were boiled in gel 
loading buffer and applied to a 10% SDS polyacrylamide 
gel, to test for expression of the fusion protein. For 
large-scale xpression, 1 litre cultures were grown and 
induced under the same conditions. The cultures were 
centrifuged in a Sorvall GSA rotor at 5500 rpm for 10 rain 
to collect cells and the pellet was resuspended in 10 ml of 
ice-cold sodium phosphate-buffered isotonic saline (PBS) 
containing 0.1 mM PMSF, to prevent proteolysis. The cells 
were lysed two times in a French Cell Press at 1400 psi 
and Triton X-100 was added to a concentration f 1%. The 
cell lysate was then centrifuged in a Sorvall SS-34 rotor at 
10000 rpm for 15 min to remove insoluble material and 
intact cells. The supernatant was collected and passed 
through a glutathione-agarose affinity column (20 ml). The 
column was washed with 3 column volumes of PBS. The 
fusion protein was eluted with 50 mM Tris-HC1 buffer (pH 
8.0), containing 5 mM reduced glutathione. The samples 
containing the fusion protein were pooled and dialysed 
overnight against hrombin cleavage buffer (50 mM Tris- 
HCI, pH 7.5, 150 mM NaCI and 2.5 mM CaCI2). 
Thrombin was added to the fusion protein sample (0.2, 
0.6 or 1% w/w fusion protein) and the mixture was 
incubated for 90 min at 25°C. The mixture was added to 
the glutathione-agarose affinity column and the released 
protein was recovered by washing the column with 1 
column volume of 50 mM Tris-HCl buffer (pH 7.5), 
containing 150 mM NaCI. The released protein was con- 
centrated using a Microsep centrifugal concentrator with a 
cut-off of 1 kDa, assayed using the Bradford protein assay 
[24], and was run on a 15% SDS-polyacrylamide g l for a 
purity check. For further purification, an asialofetuin- 
agarose affinity column (10 ml) was used for galectin 
fractionation, using conditions for absorption and elution 
as previously described [12]. For some control cell culture 
experiments, it was necessary to add unmodified GST, 
which was prepared essentially as described above, from 
cells transfected with the unmodified pGEX-4T 1 plasmid. 
N-terminal amino acid sequence analysis was carded 
out by Ms. Catriona Knight, of the Auckland Protein 
Sequencing Laboratory, on samples electroblotted from 
SDS-polyacrylamide g ls on to polyvinylidene difluoride 
membrane. Protein-staining bands in the membrane were 
cut out, and used directly for sequence analysis in a 
gas-phase protein sequencer (Applied Biosystems model 
470A). 
Erythrocyte agglutination by the recombinant lectin was 
tested using freshly-trypsinised rabbit erythrocytes [25,26]. 
Agglutination experiments were carried out with serial 
threefold ilutions of the purified fusion protein in ceramic 
tiles. Each well contained 100 /zl of 1% bovine serum 
albumin in 0.15 M NaC1, 100/zl of 0.15 M NaC1 and 100 
/~1 of erythrocyte suspension, and 100 /xl protein solution 
(1 mg. m1-1 in phosphate-buffered saline) was used to 
start the serial dilution. Iqaemagglutination experiments 
were carried out in the presence and absence of /3-mer- 
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Fig. 1. SDS-PAGE of GST, galectin-1 and GST-galectin fusion proteins. 
A. 10% SDS gel. Lane a: Mol. wt. standards (from the top of the gel; 
205, 116, 97, 67, 45 and 29 kDa). Lane b: Purified GST. Lane c: Total 
bacterial protein; putative fusion protein arrowed. B. 15% SDS gel. Lane 
a: Mol. wt. standards (from the top of the gel; 67, 45, 36, 29, 24, 20 and 
14 kDa). Lane b: Cleaved fusion protein (0.2% thrombin), Lane c: Fusion 
protein purified by glutathione-agarose chromatography. 
captoethanol (10 mM), and of lactose (100 mM), and also 
with the cleaved, recombinant galectin. Visual identifica- 
tion of the endpoint of the titration of agglutination was 
confirmed by microscopic detection of agglutinated ery- 
throcytes. 
3. Results 
Agarose gel electrophoresis of the cDNA PCR-ampli- 
fled from U20S cells with the GBP3 and GBP4 primers 
yielded a fragment of approximately 450 base-pairs, and a 
similar fragment was seen with similarly-processed cDNA 
from normal human fibroblasts, and from other human 
tumour cells (MG 63, HELA). In some cases, an additional 
250 base-pair fragment was also seen; this has not been 
further characterised. Nucleotide sequencing of the U20S 
450 base-pair cDNA fragment restricted with 
BamHI/SalI, ligated into p-GEX 4T and cloned, con- 
firmed the nucleotide sequence previously reported for 
human galectin-1 [13]. We were unable to detect a corre- 
sponding cDNA from HEP 2 cells treated in the same way 
(data not shown). 
Growth of small scale cultures of one of these clones 
confirmed the presence of a new protein of apparent 
molecular weight about 36-38 kDa in bacterial ysates 
(Fig. 1A, lane c). This corresponded to a putative fusion 
protein, and compares with the 29 kDa band which corre- 
sponds to GST (lane b). The fusion protein could be 
readily purified from large-scale bacterial culture lysates 
by affinity chromatography on glutathione-agarose. Elution 
profiles (not shown) displayed a large peak of protein 
passing unretarded through the chromatography column, 
and a much smaller peak initially retained on the column, 
and eluted by 5 mM glutathione. A 37 kDa protein was the 
major component in this glutathione-eluted fraction (Fig. 
1B, lane c), though there was also some high-molecular- 
weight protein present in some preparations. Thrombin 
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Fig. 2. SDS-PAGE of galectin-1 purified from cleaved fusion protein by 
asialofetuin-agarose affinity chromatography. A. 15% SDS gel Lanes a,b: 
Lactose-eluted galectin-1 (0.6% thrombin), at different loadings. Lanes 
c,d: Unretarded fraction, at different loadings. Lane e: Mol. wt. markers 
(from top of gel; 67, 45, 36, 29, 24, 20 and 14 kDa). B. 15% SDS gel 
Rechromatography of unretarded fraction from (A). Lane a: Unretarded 
fraction. Lane b: Fusion protein prior to cleavage and chromatography. 
Lane c: Lactose-eluted galectin-1. Lane d: Mol. wt. markers (from top of 
gel; 67, 45, 36, 29, 24, 20, 14 kDa). 
treatment (0.2% thrombin) of this purified fusion protein 
readily yielded additional bands of about 14 kDa and 29 
kDa (Fig. 1B, lane b). It was sometimes difficult to get 
total conversion of the 37 kDa band, and some experi- 
ments were done with 0.6% or 1% thrombin, in an attempt 
to improve cleavage of the fusion protein. Though success- 
ful in this aim, proteolysis of the galectin could readily 
result (see below). Attempts to separate the putative 14 
kDa galectin-1 from the other cleavage products by glu- 
tathione-agarose chromatography were not very successful, 
with all three protein components (fusion protein, galectin 
and GST) present in all fractions (not shown). Formation 
of a dimer of the 14 kDa galectin may have contributed to 
the staining intensity of the 29 kDa band (see below). 
Sephadex G-75 chromatography also failed to separate 
the products of digestion of the fusion protein (data not 
shown), but affinity chromatography on asialofetuin- 
agarose was more successful. The elution profile (not 
shown) was typical of that observed for the purification of 
natural galectin from cell extracts [12], with a larger 
protein peak unretarded by the matrix, and a smaller 
protein peak retained and eluted with 100 mM lactose. All 
three bands were observed in the material bound to 
asialofetuin-agarose, and eluted with lactose, but the 29 
kDa and 37 kDa components were relatively minor (Fig. 
2A, lanes a and b). Re-chromatography of the unretarded 
fraction on asialofetuin-agarose under the same conditions 
resulted in a purer galectin-1 preparation (Fig. 2B, lane c). 
Amino acid sequence vidence, discussed below, indicates 
that most, if not all, of the 29 kDa material remaining in 
the retarded fraction after the first asialofetuin-agarose 
chromatography step was in fact identical in sequence to 
galectin- 1. 
Two signals were clearly apparent when PTH amino 
acids were identified following automated sequential 
degradation of the 14 kDa galectin-1 band electroblotted 
from SDS-PAGE. The major signals (approx. 78%, on the 
basis of yields of PTH-amino acids) corresponded to a 
sequence gly-ser-met-ala-(-)-gly-leu-val (the fifth residue 
was unassigned), and the minor signals (ca. 22%) to 
phe-asn-ala-his-gly-asp-ala-asn. The N-terminal sequence 
of human galectin-1 has been predicted from the cDNA to 
be met-ala-cys-gly-leu-val- [13], and the additional N- 
terminal gly-ser- is expected from the sequence of the 
p-GEX linker region [21]. Amino acid sequencing was also 
carried out on material electroblotted from 29 kDa bands, 
to check the identity of this material. When the sample 
used was from the unbound protein washed off an asialofe- 
tuin column prior to the 100 mM lactose elution (i.e. the 
material from the 29 kDa band in lane (c) or (d) of Fig. 2 
A), the major signal (> 85%) corresponded to met-(-)- 
pro-ile-leu-gly-tyr, with the second residue not assigned; 
the sequence of glutathione-S-transferase is met-ser-pro- 
ile-leu-gly-tyr [27]. When the 29 kDa material from lane 
(a) of Fig. 2 B was electroblotted and sequenced, the only 
detectable sequence was gly-ser-met-ala-(-)-gly-leu, indi- 
cating that this corresponded to galectin-1, presumably 
running in SDS-PAGE as a dimer. 
Erythrocyte agglutination experiments were carried out, 
starting with a 1 mg • ml-1 solution of the fusion protein. 
Agglutination was clearly apparent in a series of threefold 
dilutions, down to a concentration of 1.3 /xg. m1-1, both 
in the presence and absense of fl-mercaptoethanol. The 
presence of lactose (100 mM) completely inhibited the 
agglutination reaction. The purified recombinant galectin 
was also an effective agglutinin at a concentration of 1.3 
/xg • ml-~. In control experiments, GST caused agglutina- 
tion at a concentration of 1 mg • ml- l ,  but was ineffective 
at lower concentrations. This was judged to be due to 
non-specific binding of dimeric GST to the erythrocytes. 
The growth-inhibitory effect of galectin-1 is demon- 
strated graphically by Fig. 3, for which HEP 2 cells were 
used. Control experiments were also carried out with the 
GST-galectin fusion protein, and with GST itself, and 
neither protein had any discernable ffect upon cell growth 
at concentrations equivalent o those of galectin-1. It is 
thus clear that the effect of galectin-1 is not due to residual 
GST or fusion protein in the galectin-1 preparations. The 
same results were found in similar control experiments 
with MPS fibroblasts (not shown); the growth-inhibitory 
effect of galectin-1 on these cells is summarised by Fig. 
4A. The fusion protein is not a growth inhibitor in the 
same concentration range, nor is unmodified GST (data not 
shown). It is clear that the inhibitory effect of galectin-1 is 
not substantially inhibited by 100 mM lactose. Quantitative 
data for the effect of galectin-1 on HEP 2 and other 
tumour cell lines is summarised in Fig. 4B. Inhibition of 
the growth of HEP2 and U20S osteosareoma cells by 
galectin-1 is clearly significant, whereas inhibition of 
growth of HELA cells is not. 
In some experiments, the inhibitory effect of galectin-1 
was clearly lower at 500/zg • ml-  1 than at 166 /zg. ml-  i. 
This phenomenon has not as yet been investigated more 
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Fig. 3. Inhibition of human turnout cell growth by recombinant galectin-1. 
Sparse cultures of human HEP 2 cells were treated with the GST-galectin 
fusion protein (left-hand rows), with cleaved and purified recombinant 
galectin-1 (centre), or with recombinant GST (right). Duplicate wells 
were treated at each concentration, starting at 500 /zg. ml-* in the case 
of galectin 1 (topmost pairs of wells, arrowed), with descending tripling 
dilutions (166, 55, 18, 6 and 2 /~g.ml-I) .  The corresponding wells 
treated with the fusion protein and with GST were at 1500, 500, 166, 55, 
18 and 6/zg-ml  -~ , in each case. The lowest pairs of wells were a control 
with normal medium in each case. The protein was dissolved in normal 
growth medium in each case, and 100 /~1 was added to replace the 
medium on the cells 24 h after plating. After 96 h, the cells were fixed 
with neutral formalin, and stained with Giemsa reagent. 
fully because of limited availability of the recombinant 
galectin, but may represent some form of galectin receptor 
down-regulation. 
Table 1 
Mitogenicity of recombinant galectin-1 
Agonist Concn. 
(/~g.ml - t )  
[3 H]Thymidine incorporation 
(relative to (relative to 
control) maximum) 
(%) 
none 
10% foetal calf serum 
Galectin-1 
Galectin- 1
(+ 100 mM lactose) 
1.0 (+0. l )  
4.8 (+0.4) 
0.2 1.6 ( + 0.2) 76 
1.0 2.1 (5:0.2) 100 
5.0 1.9 (+0.1) 90 
25.0 1.5 (+0. l )  7l 
125 0.9 (5:0.1) 43 
5.0 0.9 (+0.1) 43 
25.0 0.7 (-L- 0.1) 33 
Incorporation of [3H]thymidine into a TCA-insoluble form was measured 
in confluent MPS human fibroblast cultures in 24-well culture plates. 
Incorporation (the mean of four experimental determinations, + SEM) is 
expressed as a ratio with respect to the corresponding mean in serum-free 
controls, or is normalised relative to the maximal incorporation seen with 
galectin-l. Foetal calf serum was used as a positive control. 
The mitogenic effect of galectin- 1on MPS fibroblasts i
summarised in the Table 1. The maximal observed stimula- 
tion in thymidine incorporation is relatively modest (29%) 
compared to that seen with foetal calf serum. This activity 
is discernable at galectin concentrations at and above 0.2 
/xg • m1-1, is maximal around 1 tzg • ml-t,  and begins to 
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Fig. 4. Summary of cell growth inhibition by recombinant galectin-1. Cell cultures were established and treated with recombinant galectin-1 or other 
proteins as outlined in the legend to Fig 3. Fixed and stained cells in microwells were measured with an ELISA spectrophotometer equipped with a 540-nm 
filter. Cell growth is expressed as the percentage of the staining intensity seen with corresponding normal controls. Each point represents he mean of at 
least four determinations (5: S.E.M.), but error bars are included in only one data set for clarity. A. • MPS human fibroblasts treated with galectin-1. [] 
MPS fibroblasts treated with GST-galectin fusion protein. • MPS fibroblasts treated with galectin-I and 100 mM lactose. B. • HEP 2 carcinoma cells 
treated with galectin-l. [] HEP 2 cells treated with fusion protein. © U2 OS osteosarcoma cells treated with galectin-1. • HELA carcinoma cells treated 
with galectin-1. 
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decline at higher concentrations. It is clearly inhibited by 
lactose. 
The question of possible cytotoxic effects of galectin-1 
has been addressed. In experiments on MPS fibroblast 
proliferation, some cell detachment from the substratum 
was observed in culture wells treated with galectin-1. 
When this reagent was added to newly confluent MPS 
cultures for periods of 48 h, at the same concentrations a
used to demonstrate inhibition of cell growth, there was no 
observable cell detachment, and the viability of the cells 
was unaffected. Trypan Blue exclusion indicated viabilty 
of > 98% in both test and control culture wells. 
4. Discussion 
The recombinant protein is clearly a lectin, as demon- 
strated by the haemagglutination reaction. This reaction is 
inhibited by lactose, which is consistent with the known 
specificity of galectin-1. It is noteworthy that the GST- 
galectin fusion protein is also a functional ectin. The 
dependence of haemagglutination on thiol reduction, gen- 
erally considered characteristic of galectins [28], was not 
observed in these experiments. 
Amino acid sequencing confirmed that the recombinant 
protein was indeed derived from the galectin-1 gene. Apart 
from the non-assigned residue at cycle 6, the sequence was 
identical to that predicted for galectin-I [13], with an 
N-terminal dipeptide extension derived from the p-GEX 
linker region. The sequencing experiments also provided 
some evidence for thrombin degradation of the recombi- 
nant protein during cleavage of the fusion protein; the 
minor sequence observed corresponds to the eight amino 
acid residues C-terminal to arginine-48 in the galectin-1 
sequence. This minor component was inseparable from the 
intact recombinant galectin by SDS-PAGE, so it seems 
likely that the N-terminal peptide generated by thrombin 
cleavage at arg-48 remains attached to the rest of the 
protein, perhaps due to the intramolecular disulphide bonds 
in galectin-1 [29]. There was also some evidence for the 
survival in SDS-PAGE of galectin-1 dimers. 
Recombinant galectin-1 can act as a growth inhibitor 
for human fibroblasts, and for some human tumour cells. 
The GST-galectin fusion protein does not share this prop- 
erty, but the haemagglutination titres observed with the 
fusion protein and with the purified recombinant galectin 
were quantitatively similar. Taken together, these obseva- 
tions are a strong indication that growth inhibition does not 
depend upon the carbohydrate binding site. The anomalous 
mobility on SDS electrophoresis may indicate unusual 
structural interactions within the fusion protein, which may 
disrupt the site responsible for cell growth inhibition, but 
not the carbohydrate-binding site. The mobility in SDS- 
PAGE of the fusion protein corresponded to a kDa of 
about 37, whereas a value of about 43-44 kDa would be 
expected from the known molecular weights of the two 
components. 
In comparing the experiments on thymidine incorpora- 
tion and growth inhibition, it should be realised that inhibi- 
tion of thymidine incorporation is measured relative to 
baseline incorporation in serum-free medium in the ab- 
sence of mitogenic stimulus, whereas inhibition of cell 
growth is measured against abackground of normal growth 
in complete medium. The mitogenic activity of galectin-1 
is seen in a relatively low concentration range, and is 
dependent upon the fl-galactoside binding site, as it is 
inhibited by lactose. The growth-inhibitory property of the 
lectin is only apparent in a higher concentration range, and 
is largely unaffected by lactose. This offers further confir- 
mation that growth inhibition is not primarily due to the 
fl-galactoside binding site. Galectin-1 is apparently not 
cytotoxic. 
Experiments with recombinant murine galectin-1 ex- 
pressed in a eukaryotic COS-I cell system suggest that it is 
not a functional lectin, by virtue of a endogenous glycan 
component which binds non-covalently to the fl-galacto- 
side binding site. In the absence of the glycan component, 
the protein is less effective as a growth inhibitor [30]. The 
physiological significance of the endogenous glycan com- 
ponent is unclear. Obviously, it is absent from bacterially- 
expressed galectins, but the intrinsic lectin activity which 
is the basis for identification of most natural mammalian 
isolates suggests that it may not always, or even usually, 
be present on these proteins. A novel and intriguing possi- 
bility is that the glycan is itself a modulator of galectin 
growth-modulatory activity, with the potential to minimise 
non-productive or mitogenic interactions, and to maximise 
growth-inhibitory actions. 
The murine recombinant galectin-1 was considerably 
more effective as a growth inhibitor, but direct comparison 
is difficult because this protein was expressed in eukary- 
otic cells and tested on murine fibroblasts [11]. Our bacte- 
rially-expressed galectin-1 is apparently 5-10-fold less 
effective as a growth inhibitor than the natural human 
protein [12]. This difference is clearly not connected with 
the presence of a glycan similar to that reported by Wells 
and Mallucci [30], as both the natural and recombinant 
human proteins have been isolated on the basis of their 
affinity for fl-galactosides. The partial proteolysis of the 
galectin, already discussed above, may contribute to this 
effect, but there must also be some other more important 
cause which has not yet been identified. One possibility is 
that the residual linker amino acids from the fusion protein 
also reduce growth-inhibitory activity. Yields of natural 
galectin from conditioned cell culture medium were so low 
[12], that it was not practicable to make a more extensive 
comparison between it and the bacterial recombinant pro- 
tein. We cannot, on the basis of the evidence obtained with 
this recombinant form of galectin-1, accurately assess the 
physiological significance of the biphasic cellular re- 
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sponse, as the concentration response range may be differ- 
ent from that with the natural protein. 
An autocrine growth factor from a transformed rat cell 
line has been claimed to be related to rat lung galectin-1 
[31], and overexpression f rat galectin-1 cDNA in mouse 
fibroblasts resulted in transformation. There was a strong 
clonal correlation between transformation a d the appear- 
ance of agglutinating activity in the culture medium. /3- 
galactosides which inhibited the agglutination did not af- 
fect autocrine stimulation of DNA synthesis [32]. The 
mitogenic mechanism was thus apparently not due to lectin 
activity, as has been the case in most studies on galectins 
so far. 
The concept of a bioactive peptide with both growth- 
stimulatory and growth-inhibitory activities is not new. It 
has been well-established that transforming rowth factor 
/3 (TGF/3) has a biphasic effect on some cell types, and a 
model, combining this concept with the chemotactic prop- 
erty of TGF/3, has been proposed to account for sequential 
cell migration, proliferation and differentiation i  response 
to this growth factor [33]. Using natural galectin-1, we 
have previously observed a growth-stimulatory effect on 
bovine corneal endothelial cells [12], suggesting that these 
cells have a different concentration response range for 
galectin, and responded positively at concentrations which 
caused a negative ffect in the other human cells. 
Changes in the cellular levels of galectin-1 and anti- 
genically-related proteins have been linked to mitogenic 
stimulation and tumour transformation i human leuko- 
cytes [34]. A recent report confirms that the anti-tumour 
action of sodium butyrate is linked to the induction of 
galectin-1 gene expression i human coloncarcinoma cells, 
and the subsequent re-differentiation f the cells [35]. It 
may thus be significant hat we were unable to detect 
galectin-1 gene expression in HEP 2 cells. Since these 
cells still respond to the growth-inhibitory action of 
galectin-1, their apparent failure to synthesise the lectin 
may contribute to their transformation. However, in sev- 
eral other cell types, galectin-I expression is increased 
following tumour transformation. The concomitant eleva- 
tion of expression of glycoproteins able to bind to galectin-1 
may be significant in this context [34-37]. 
In our earlier experiments with natural human galectin- 1, 
we observed inhibition of the growth of human fibroblasts 
and of U2 OS osteosarcoma cells, but not of HELA 
carcinoma cells. We attributed the apparent failure of 
galectin-1 to inhibit the growth of HELA cells as circum- 
stantial support for the hypothesis that continuous galectin 
degradation by the GRP occurs in normal cells, and is 
necessary for cell growth [12], since inhibition of the GRP 
does not inhibit HELA cell growth [4,6]. Growth inhibition 
by proteinase inhibitors is also seen with HEP2 cells [6], 
which nevertheless are subject to growth inhibition by 
galectin-1. The relationship between GRP action and the 
role of galectin-1 is cle~.rly not as simple as we have 
previously postulated. 
The present report provides some further evidence to 
suggest hat galectin-1 is particularly susceptible to prote- 
olysis, but the possible effects of thrombin or E. coli 
proteinases may not equate with those of human cell- 
surface enzymes, and direct experimental investigation of 
galectin-I degradation by cultured cells is an obvious 
extension of this work. Sensitivity to trypsin and staphylo- 
coccal V8 proteinase degradation has been observed with 
recombinant bovine galectin-1 synthesised in vitro [38]. 
At first sight, the activity of galectin-1 as an inhibitor of 
tumour cell growth has obvious potential for application. 
However, galectin-1 has both positive and negative 
growth-regulatory properties, depending on circumstances. 
Production of recombinant galectin-1 in a eukaryotic ex- 
pression system may minimise or eliminate this difficulty, 
by the generation of galectin-glycan conjugates, as dis- 
cussed above, but the nature of the galectin-glycan interac- 
tion requires further study. An alternative to the use of 
such conjugates could result from site-directed mutagene- 
sis to inactivate the fl-galactoside binding site, and consid- 
erable progress has already been made towards this aim 
[38]. A recombinant version of galectin-1, lacking /3- 
galactoside binding activity but retaining its growth-inhibi- 
tory site, could be suitable for therapeutic use. Site-di- 
rected mutagenesis may also be of value in the creation of 
proteinase-resistant forms of this cell growth effector. 
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